ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,870.62
-1.32%
US Tech 100
19,880.00
-2.30%
Dow Jones
43,444.99
-0.70%
Brent Oil
71.25
0.50%
Bitcoin
91,036.36
-0.03%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. PMV Pharmaceuticals Inc (PMVP)

  7. PMV Pharmaceuticals Inc (PMVP) News

PMV Pharmaceuticals Inc

PMV Pharmaceuticals Inc (PMVP)

NASDAQ
1.61
0.01
(0.63%)
Closed November 16 4:00PM
Delayed by 15 minutes
1.60
-0.01
(-0.62%)
After Hours: 7:59PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

PMVP News

Official News Only

Form 3 - Initial statement of beneficial ownership of securities
Edgar (US Regulatory)
January 11 2024
PMVP (0.63%)

Form 8-K - Current report
Edgar (US Regulatory)
January 05 2024
PMVP (0.63%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
November 09 2023
PMVP (0.63%)

Form 8-K - Current report
Edgar (US Regulatory)
November 09 2023
PMVP (0.63%)

Form 8-K - Current report
Edgar (US Regulatory)
October 12 2023
PMVP (0.63%)

Form 8-K - Current report
Edgar (US Regulatory)
October 11 2023
PMVP (0.63%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 18 2023
PMVP (0.63%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 18 2023
PMVP (0.63%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
August 09 2023
PMVP (0.63%)

PMVP Discussion

View Posts
Monksdream Monksdream 8 months ago
PMVP under $2
👍️0
Mt. Blanc Mt. Blanc 10 months ago
PMVP had a great move over $3 but then lost control of the jet and sank quickly.
👍️0
Mt. Blanc Mt. Blanc 11 months ago
PMVP into the cup and handle chart setup. On radar to begin climbing the great wall of worry.

mb
👍️0
Mt. Blanc Mt. Blanc 1 year ago
$PMVP trading in the low $2's for now but at some point, this starts to firm up well into 2024+.

mb
👍️0
Mt. Blanc Mt. Blanc 1 year ago
PMVP will be under radar for a while until it catches fire and then will be seen.

mb
👍️0
crudeoil24 crudeoil24 2 years ago
2022 American Society of Clinical Oncology (ASCO) Annual Meeting
👍️0
crudeoil24 crudeoil24 2 years ago
JUNE 7 > Updated data from ongoing Phase 1/2 PYNNACLE trial to be presented .
👍️0
crudeoil24 crudeoil24 2 years ago
PMV Pharma Shares Rise 17%; Company to Present Data on PYNNACLE Phase 1 Trial
6:46 pm ET May 26, 2022 (Dow Jones) Print

By Stephen Nakrosis


Shares of PMV Pharmaceuticals Inc. were trading higher in Thursday's after-hours market, following the company's announcement that it would be presenting data from its lead program, PC14586, at the 2022 American Society of Clinical Oncology meeting next month.

PMV said its abstract describes "preliminary outcomes from 29 patients, including 21 efficacy evaluable, from the ongoing Phase 1/2 PYNNACLE trial of PC14586 in patients with advanced solid tumors that have a p53 Y220C mutation." PMV said the preliminary results "represent the first clinical evidence of targeting a p53 Y220C mutation."

At 6:37 p.m. ET, PMV's shares were trading 17.79% higher at $15.56 a share. Volume at the time topped 2.1 million shares. The company's stock finished the day with a 0.92% gain, closing at $13.21 a share.


Write to Stephen Nakrosis at stephen.nakrosis@wsj.com


(END) Dow Jones Newswires

PMVP
👍️0
crudeoil24 crudeoil24 2 years ago
PMV Pharmaceuticals, Inc. is a precision oncology company, which is engaged in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The Company’s lead product candidate, PC14586, is an orally available small molecule designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild type p53. PC14586 is designed to restore the wild-type conformation by occupying the crevice created by the tyrosine to cysteine mutation in amino acid position 220. The Company is also using its precision oncology platform to develop a pipeline of oral small molecule product candidates, which structurally correct other p53 hotspot mutations to restore their wild-type function and product candidates that target certain cancers where wild-type p53 function is silenced.

PMVP
👍️0

Your Recent History

NASDAQ
PMVP
PMV Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved